Addex Therapeutics (ADXN) Equity Ratio: 2022-2025
Historic Equity Ratio for Addex Therapeutics (ADXN) over the last 1 years, with Jun 2025 value amounting to -41.93.
- Addex Therapeutics' Equity Ratio fell 63.81% to -41.93 in Q2 2025 from the same period last year, while for Jun 2025 it was -41.93, marking a year-over-year decrease of 63.81%. This contributed to the annual value of 0.91 for FY2024, which is 267.25% up from last year.
- According to the latest figures from Q2 2025, Addex Therapeutics' Equity Ratio is -41.93, which was down 12.08% from -37.41 recorded in Q1 2025.
- In the past 5 years, Addex Therapeutics' Equity Ratio registered a high of 0.91 during Q4 2024, and its lowest value of -108.96 during Q1 2024.
- Over the past 3 years, Addex Therapeutics' median Equity Ratio value was -31.50 (recorded in 2024), while the average stood at -35.46.
- Its Equity Ratio has fluctuated over the past 5 years, first skyrocketed by 267.25% in 2024, then plummeted by 63.81% in 2025.
- Addex Therapeutics' Equity Ratio (Quarterly) stood at 0.59 in 2022, then slumped by 58.40% to 0.25 in 2023, then spiked by 267.25% to 0.91 in 2024, then slumped by 63.81% to -41.93 in 2025.
- Its Equity Ratio stands at -41.93 for Q2 2025, versus -37.41 for Q1 2025 and 0.91 for Q4 2024.